American Association for Cancer Research (AACR)
Blood Cancer Discovery
,  volume 6 ,  issue 3 ,  pages OF1-OF9

Brexucabtagene autoleucel versus allogeneic hematopoietic cell transplantation in relapsed and refractory mantle cell lymphoma

Nora Liebers 1, 2, 3, 4, 5
, 
Ariane Boumendil 6, 7
, 
Hervé Finel 7, 8
, 
Dominic Edelmann 9, 10
, 
Guido Kobbe 1, 2, 4
, 
Ben-Niklas Baermann 1, 2, 4
, 
Yasmina Serroukh 11, 12
, 
D. Blaise 13, 14
, 
DIETRICH W. BEELEN 15, 16
, 
C Solano 17, 18
, 
Maija Itälä Remes 19, 20
, 
Tom van Meerten 21, 22
, 
Goda Choi 22, 23
, 
Susanne A C. Schmidt 1, 2, 4
, 
Manuel A. Friese 24, 25
, 
Jenny Byrne 26, 27
, 
J. J. Tudesq 28, 29
, 
Anna Ossami Saidy 30, 31
, 
Ana Nunes 32, 33
, 
Rubina Siddiqi 32, 33
, 
Elande Baro 32, 33
, 
Dan Zheng 32, 33
, 
Ioana Kloos 32, 33
, 
PETER DREGER 5, 7, 34
, 
Anna Sureda 7, 35, 36
, 
Bertram Glass 7, 31, 37
, 
Sascha Dietrich 2, 4, 5, 7, 38
1
 
University Hospital Duesseldorf, Duesseldorf, Germany | 
2
 
1Department of Hematology, Oncology and Clinical Immunology, University Hospital Duesseldorf, Duesseldorf, Germany. | 
3
 
4
 
3Center for Integrated Oncology Aachen-Bonn-Cologne-Düsseldorf (CIO ABCD), Aachen Bonn Cologne Düsseldorf, Cologne, Germany. | 
5
 
6
 
Hospital Saint-Antoine, France | 
7
 
5Lymphoma Working Party, European Society for Blood and Marrow Transplantation, Paris, France. | 
8
 
Lymphoma Working Party, European Society for Blood and Marrow Transplantation, France | 
9
 
10
 
11
 
12
 
13
 
14
 
15
 
16
 
17
 
18
 
19
 
20
 
21
 
22
 
23
 
24
 
25
 
26
 
27
 
28
 
CHU Lapeyronie, France | 
29
 
15CHU Lapeyronie, Montpellier, France. | 
30
 
31
 
16Department of Hematology, HELIOS Klinikum Berlin-Buch, Berlin, Germany. | 
32
 
Kite, a Gilead Company, United States | 
33
 
17Kite, a Gilead Company, Santa Monica, California. | 
34
 
35
 
36
 
37
 
Department of Haematology and Stem Cell Transplantation, Helios Clinic, Berlin-Buch, Germany | 
38
 
Publication type: Journal Article
Publication date: 2025-02-06
American Association for Cancer Research (AACR)
scimago Q1
wos Q1
SJR: 4.316
CiteScore: 15.8
Impact factor: 11.5
ISSN: 26433230, 26433249
Abstract

Brexucabtagene autoleucel (brexu-cel) and allogeneic hematopoietic cell transplantation (alloHCT) are effective treatments for relapsed and refractory mantle cell lymphoma (r/r MCL), but the optimal choice remains unclear. We conducted an analysis of 64 patients aged ≥50 years with r/r MCL treated with brexu-cel in the ZUMA-2 study, matching them 1:1 by propensity score to 64 (of 272) patients with r/r MCL who underwent alloHCT using data from the European Society for Blood and Marrow Transplantation registry. The median follow-up time was 36.5 months for the brexu-cel cohort and 34.1 months for the matched alloHCT cohort. Patients who received brexu-cel had a significantly higher overall survival [(OS) 81.3% vs. 59.2%; HR, 0.39; P = 0.004] and lower nonrelapse mortality (3.6% vs. 21.2%; P = 0.015) 1 year after treatment. Chronic GVHD occurred within the first year in 26.9% of patients who underwent alloHCT. However, long-term progression-free survival (PFS) and OS remain comparable. Despite the limitations of this nonrandomized study, the findings indicate a superior safety profile for brexu-cel in r/r MCL.

Significance:

Patients aged ≥50 years with r/r MCL had superior OS and lower nonrelapse mortality 1 year after receiving brexu-cel compared with alloHCT. However, the long-term PFS and OS are similar for both treatments. Individual risk–benefit evaluation is essential to guide optimal treatment decisions.

Found 
Found 

Top-30

Journals

1
Bone Marrow Transplantation
Bone Marrow Transplantation, 1, 20%
Bone Marrow Transplantation
1 publication, 20%
Best Practice and Research in Clinical Haematology
Best Practice and Research in Clinical Haematology, 1, 20%
Best Practice and Research in Clinical Haematology
1 publication, 20%
Hematological Oncology
Hematological Oncology, 1, 20%
Hematological Oncology
1 publication, 20%
Cancers
Cancers, 1, 20%
Cancers
1 publication, 20%
HemaSphere
HemaSphere, 1, 20%
HemaSphere
1 publication, 20%
1

Publishers

1
2
Wiley
Wiley, 2, 40%
Wiley
2 publications, 40%
Springer Nature
Springer Nature, 1, 20%
Springer Nature
1 publication, 20%
Elsevier
Elsevier, 1, 20%
Elsevier
1 publication, 20%
MDPI
MDPI, 1, 20%
MDPI
1 publication, 20%
1
2
  • We do not take into account publications without a DOI.
  • Statistics recalculated weekly.

Are you a researcher?

Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
5
Share
Cite this
GOST |
Cite this
GOST Copy
Liebers N. et al. Brexucabtagene autoleucel versus allogeneic hematopoietic cell transplantation in relapsed and refractory mantle cell lymphoma // Blood Cancer Discovery. 2025. Vol. 6. No. 3. p. OF1-OF9.
GOST all authors (up to 50) Copy
Liebers N. et al. Brexucabtagene autoleucel versus allogeneic hematopoietic cell transplantation in relapsed and refractory mantle cell lymphoma // Blood Cancer Discovery. 2025. Vol. 6. No. 3. p. OF1-OF9.
RIS |
Cite this
RIS Copy
TY - JOUR
DO - 10.1158/2643-3230.bcd-24-0178
UR - https://aacrjournals.org/bloodcancerdiscov/article/doi/10.1158/2643-3230.BCD-24-0178/751663/Brexucabtagene-autoleucel-versus-allogeneic
TI - Brexucabtagene autoleucel versus allogeneic hematopoietic cell transplantation in relapsed and refractory mantle cell lymphoma
T2 - Blood Cancer Discovery
AU - Liebers, Nora
AU - Boumendil, Ariane
AU - Finel, Hervé
AU - Edelmann, Dominic
AU - Kobbe, Guido
AU - Baermann, Ben-Niklas
AU - Serroukh, Yasmina
AU - Blaise, D.
AU - BEELEN, DIETRICH W.
AU - Solano, C
AU - Itälä Remes, Maija
AU - van Meerten, Tom
AU - Choi, Goda
AU - Schmidt, Susanne A C.
AU - Friese, Manuel A.
AU - Byrne, Jenny
AU - Tudesq, J. J.
AU - Ossami Saidy, Anna
AU - Nunes, Ana
AU - Siddiqi, Rubina
AU - Baro, Elande
AU - Zheng, Dan
AU - Kloos, Ioana
AU - DREGER, PETER
AU - Sureda, Anna
AU - Glass, Bertram
AU - Dietrich, Sascha
PY - 2025
DA - 2025/02/06
PB - American Association for Cancer Research (AACR)
SP - OF1-OF9
IS - 3
VL - 6
SN - 2643-3230
SN - 2643-3249
ER -
BibTex |
Cite this
BibTex (up to 50 authors) Copy
@article{2025_Liebers,
author = {Nora Liebers and Ariane Boumendil and Hervé Finel and Dominic Edelmann and Guido Kobbe and Ben-Niklas Baermann and Yasmina Serroukh and D. Blaise and DIETRICH W. BEELEN and C Solano and Maija Itälä Remes and Tom van Meerten and Goda Choi and Susanne A C. Schmidt and Manuel A. Friese and Jenny Byrne and J. J. Tudesq and Anna Ossami Saidy and Ana Nunes and Rubina Siddiqi and Elande Baro and Dan Zheng and Ioana Kloos and PETER DREGER and Anna Sureda and Bertram Glass and Sascha Dietrich and others},
title = {Brexucabtagene autoleucel versus allogeneic hematopoietic cell transplantation in relapsed and refractory mantle cell lymphoma},
journal = {Blood Cancer Discovery},
year = {2025},
volume = {6},
publisher = {American Association for Cancer Research (AACR)},
month = {feb},
url = {https://aacrjournals.org/bloodcancerdiscov/article/doi/10.1158/2643-3230.BCD-24-0178/751663/Brexucabtagene-autoleucel-versus-allogeneic},
number = {3},
pages = {OF1--OF9},
doi = {10.1158/2643-3230.bcd-24-0178}
}
MLA
Cite this
MLA Copy
Liebers, Nora, et al. “Brexucabtagene autoleucel versus allogeneic hematopoietic cell transplantation in relapsed and refractory mantle cell lymphoma.” Blood Cancer Discovery, vol. 6, no. 3, Feb. 2025, pp. OF1-OF9. https://aacrjournals.org/bloodcancerdiscov/article/doi/10.1158/2643-3230.BCD-24-0178/751663/Brexucabtagene-autoleucel-versus-allogeneic.